Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of Ultra-Low Dose Estradiol and Dydrogesterone for Vasomotor Symptoms
NCT00251082Phase 3Completed
- Sponsor
- Solvay
- Start
- Dec 2005
- Primary completion
- Oct 2007
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of estradiol and dydrogesterone in vasomotor symptoms (3 arms), sponsored by Solvay. Primary endpoint: Change in the number of moderate to severe hot flushes at 13 weeks. Started Dec 2005; status: completed.
02
Drugs
estradioldydrogesterone
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT00251082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251082.